PMC:7102662 / 17171-17988 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T41","span":{"begin":203,"end":210},"obj":"Body_part"},{"id":"T42","span":{"begin":225,"end":239},"obj":"Body_part"},{"id":"T43","span":{"begin":302,"end":307},"obj":"Body_part"}],"attributes":[{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma14067"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T155","span":{"begin":106,"end":109},"obj":"Disease"},{"id":"T156","span":{"begin":130,"end":138},"obj":"Disease"},{"id":"T157","span":{"begin":252,"end":260},"obj":"Disease"},{"id":"T158","span":{"begin":361,"end":369},"obj":"Disease"},{"id":"T159","span":{"begin":466,"end":469},"obj":"Disease"},{"id":"T160","span":{"begin":754,"end":757},"obj":"Disease"},{"id":"T161","span":{"begin":800,"end":808},"obj":"Disease"}],"attributes":[{"id":"A155","pred":"mondo_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A156","pred":"mondo_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A157","pred":"mondo_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A158","pred":"mondo_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A159","pred":"mondo_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A160","pred":"mondo_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A161","pred":"mondo_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T104","span":{"begin":6,"end":9},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T105","span":{"begin":15,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T106","span":{"begin":225,"end":239},"obj":"http://purl.obolibrary.org/obo/CL_0000746"},{"id":"T107","span":{"begin":296,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T108","span":{"begin":318,"end":319},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T24","span":{"begin":49,"end":63},"obj":"Chemical"},{"id":"T25","span":{"begin":53,"end":63},"obj":"Chemical"},{"id":"T26","span":{"begin":65,"end":69},"obj":"Chemical"},{"id":"T27","span":{"begin":75,"end":86},"obj":"Chemical"},{"id":"T28","span":{"begin":461,"end":465},"obj":"Chemical"},{"id":"T29","span":{"begin":749,"end":753},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T142","span":{"begin":0,"end":148},"obj":"Sentence"},{"id":"T143","span":{"begin":149,"end":245},"obj":"Sentence"},{"id":"T144","span":{"begin":246,"end":470},"obj":"Sentence"},{"id":"T145","span":{"begin":471,"end":561},"obj":"Sentence"},{"id":"T146","span":{"begin":562,"end":638},"obj":"Sentence"},{"id":"T147","span":{"begin":639,"end":817},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T274","span":{"begin":53,"end":63},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T275","span":{"begin":87,"end":104},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T276","span":{"begin":130,"end":138},"obj":"SP_7"},{"id":"T277","span":{"begin":173,"end":183},"obj":"GO:0010467"},{"id":"T278","span":{"begin":187,"end":191},"obj":"G_3;PG_10;PR:000003622"},{"id":"T279","span":{"begin":203,"end":210},"obj":"UBERON:0000479"},{"id":"T280","span":{"begin":225,"end":239},"obj":"CL:0000746"},{"id":"T281","span":{"begin":252,"end":262},"obj":"SP_7"},{"id":"T282","span":{"begin":272,"end":276},"obj":"G_3;PG_10;PR:000003622"},{"id":"T283","span":{"begin":296,"end":301},"obj":"SP_6;NCBITaxon:9606"},{"id":"T284","span":{"begin":361,"end":369},"obj":"SP_7"},{"id":"T285","span":{"begin":800,"end":808},"obj":"SP_7"},{"id":"T29868","span":{"begin":24,"end":29},"obj":"NCBITaxon:10239"},{"id":"T44693","span":{"begin":81,"end":86},"obj":"SP_6;NCBITaxon:9606"},{"id":"T30153","span":{"begin":87,"end":92},"obj":"UBERON:0000948"},{"id":"T84285","span":{"begin":132,"end":142},"obj":"UBERON:0002349"},{"id":"T53976","span":{"begin":157,"end":162},"obj":"NCBITaxon:10239"},{"id":"T87440","span":{"begin":225,"end":235},"obj":"UBERON:0002349"},{"id":"T16635","span":{"begin":250,"end":258},"obj":"SP_7"},{"id":"T1147","span":{"begin":314,"end":330},"obj":"UBERON:0002084"},{"id":"T55144","span":{"begin":360,"end":376},"obj":"UBERON:0002084"},{"id":"T79081","span":{"begin":481,"end":486},"obj":"UBERON:0000948"},{"id":"T98834","span":{"begin":498,"end":506},"obj":"SP_7"},{"id":"T81730","span":{"begin":521,"end":526},"obj":"UBERON:0000948"},{"id":"T81536","span":{"begin":588,"end":592},"obj":"GO:0016265"},{"id":"T85605","span":{"begin":735,"end":743},"obj":"SP_7"},{"id":"T316","span":{"begin":53,"end":63},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T317","span":{"begin":87,"end":104},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T318","span":{"begin":130,"end":138},"obj":"SP_7"},{"id":"T319","span":{"begin":173,"end":183},"obj":"GO:0010467"},{"id":"T320","span":{"begin":187,"end":191},"obj":"G_3;PG_10;PR:000003622"},{"id":"T321","span":{"begin":203,"end":210},"obj":"UBERON:0000479"},{"id":"T322","span":{"begin":225,"end":239},"obj":"CL:0000746"},{"id":"T323","span":{"begin":252,"end":262},"obj":"SP_7"},{"id":"T324","span":{"begin":272,"end":276},"obj":"G_3;PG_10;PR:000003622"},{"id":"T325","span":{"begin":296,"end":301},"obj":"SP_6;NCBITaxon:9606"},{"id":"T326","span":{"begin":361,"end":369},"obj":"SP_7"},{"id":"T327","span":{"begin":800,"end":808},"obj":"SP_7"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"2_test","denotations":[{"id":"32247212-15897343-25241183","span":{"begin":241,"end":243},"obj":"15897343"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"498","span":{"begin":49,"end":52},"obj":"Gene"},{"id":"499","span":{"begin":187,"end":191},"obj":"Gene"},{"id":"500","span":{"begin":272,"end":276},"obj":"Gene"},{"id":"501","span":{"begin":252,"end":262},"obj":"Species"},{"id":"502","span":{"begin":296,"end":301},"obj":"Species"},{"id":"503","span":{"begin":407,"end":415},"obj":"Species"},{"id":"504","span":{"begin":783,"end":790},"obj":"Species"},{"id":"505","span":{"begin":130,"end":138},"obj":"Disease"},{"id":"506","span":{"begin":361,"end":369},"obj":"Disease"},{"id":"507","span":{"begin":800,"end":808},"obj":"Disease"}],"attributes":[{"id":"A498","pred":"tao:has_database_id","subj":"498","obj":"Gene:1636"},{"id":"A499","pred":"tao:has_database_id","subj":"499","obj":"Gene:59272"},{"id":"A500","pred":"tao:has_database_id","subj":"500","obj":"Gene:59272"},{"id":"A501","pred":"tao:has_database_id","subj":"501","obj":"Tax:2697049"},{"id":"A502","pred":"tao:has_database_id","subj":"502","obj":"Tax:9606"},{"id":"A503","pred":"tao:has_database_id","subj":"503","obj":"Tax:9606"},{"id":"A504","pred":"tao:has_database_id","subj":"504","obj":"Tax:9606"},{"id":"A505","pred":"tao:has_database_id","subj":"505","obj":"MESH:C000657245"},{"id":"A506","pred":"tao:has_database_id","subj":"506","obj":"MESH:C000657245"},{"id":"A507","pred":"tao:has_database_id","subj":"507","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. However, to date, no experimental or clinical data have emerged to support these concerns. At the same time, the risks of discontinuing these therapies are well known. Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]."}